27/11/2020
The European Medicines Agency has published their latest questions and answers for stakeholders, regarding the implementation of Protocol on Ireland/Northern Ireland after the Brexit transition period; with key considerations for safety reporting, Eudravigilance, EudraCT, PSUR Repository, Product Information, GMP and manufacturing, parallel distribution and more.
For information: